Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

PATTI, Angelo Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.946
EU - Europa 3.843
AS - Asia 2.799
SA - Sud America 459
AF - Africa 78
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 6
Totale 13.147
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.857
IT - Italia 1.253
SG - Singapore 1.044
RU - Federazione Russa 862
CN - Cina 673
DE - Germania 359
FI - Finlandia 355
BR - Brasile 351
VN - Vietnam 265
HK - Hong Kong 264
PL - Polonia 199
GB - Regno Unito 159
FR - Francia 151
UA - Ucraina 146
JP - Giappone 107
IE - Irlanda 104
IN - India 71
SE - Svezia 63
BD - Bangladesh 61
KR - Corea 61
CA - Canada 41
RO - Romania 37
IQ - Iraq 33
AR - Argentina 32
TR - Turchia 30
AT - Austria 29
MX - Messico 29
IR - Iran 27
BE - Belgio 23
CI - Costa d'Avorio 20
ES - Italia 20
PK - Pakistan 19
MY - Malesia 18
TH - Thailandia 18
UZ - Uzbekistan 17
ZA - Sudafrica 17
CZ - Repubblica Ceca 15
NL - Olanda 15
AU - Australia 14
CL - Cile 14
SA - Arabia Saudita 14
VE - Venezuela 13
CO - Colombia 11
EC - Ecuador 11
NP - Nepal 10
PH - Filippine 10
CH - Svizzera 9
GR - Grecia 9
AE - Emirati Arabi Uniti 8
ID - Indonesia 8
IL - Israele 8
KE - Kenya 8
BG - Bulgaria 7
BO - Bolivia 7
MA - Marocco 7
PE - Perù 7
DK - Danimarca 6
EG - Egitto 6
JM - Giamaica 6
PY - Paraguay 6
JO - Giordania 5
DZ - Algeria 4
ET - Etiopia 4
EU - Europa 4
LB - Libano 4
LT - Lituania 4
SY - Repubblica araba siriana 4
UY - Uruguay 4
AL - Albania 3
AO - Angola 3
AZ - Azerbaigian 3
CR - Costa Rica 3
GY - Guiana 3
TN - Tunisia 3
TW - Taiwan 3
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
GE - Georgia 2
HU - Ungheria 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
QA - Qatar 2
RS - Serbia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
BZ - Belize 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
IM - Isola di Man 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
ME - Montenegro 1
Totale 13.134
Salva come PNG Salva come JPEG
Città #
Ashburn 733
Singapore 731
Fairfield 556
Chandler 406
San Jose 355
Wilmington 255
Hong Kong 251
Woodbridge 251
Houston 225
Seattle 221
Cambridge 184
Ann Arbor 164
Zgierz 163
Palermo 145
Moscow 144
Council Bluffs 134
Beijing 124
Des Moines 109
Medford 109
Rome 105
Tokyo 104
Dublin 103
Santa Clara 95
Los Angeles 94
New York 90
Ho Chi Minh City 83
Jacksonville 77
Dallas 76
Lauterbourg 72
Princeton 68
Altamura 67
Nanjing 67
Frankfurt am Main 65
Milan 65
Helsinki 59
Boardman 55
Hanoi 54
Lawrence 51
The Dalles 41
San Diego 39
São Paulo 35
Buffalo 34
Chicago 34
Hefei 33
Jinan 30
Tulsa 26
Changsha 25
Dearborn 25
London 25
Warsaw 25
Nuremberg 24
Shenyang 24
Orem 23
Da Nang 22
Nanchang 22
Abidjan 20
Brussels 20
Tianjin 20
Hebei 19
Atlanta 18
Bangkok 18
Redwood City 18
Baghdad 17
Guangzhou 17
Munich 17
Naples 17
Ningbo 17
Columbus 16
Florence 16
Ludwigshafen am Rhein 16
Rio de Janeiro 16
Tehran 16
Boston 14
Brooklyn 14
Chennai 14
Phoenix 14
Poplar 14
Amsterdam 13
Bari 13
Denver 13
Haiphong 13
Johannesburg 13
Montreal 13
Verona 13
Jiaxing 12
Catania 11
Napoli 11
San Paolo di Civitate 11
Cardiff 10
Falls Church 10
Melbourne 10
Paris 10
Stockholm 10
Vienna 10
Brno 9
Cagliari 9
Kuala Lumpur 9
Kumar 9
Manchester 9
Pisa 9
Totale 7.815
Salva come PNG Salva come JPEG
Nome #
PROBIOTICI E TERAPIA CONVENZIONALE: NUOVE FRONTIERE NELLA GESTIONE DELLE MANIFESTAZIONI ARTICOLARI DELLE MALATTIE INFIAMMATORIE INTESTINALI (IBD) 843
Bergamot reduces plasma lipids, atherogenic small dense LDL, and subclinical atherosclerosis in subjects with moderate hypercholesterolemia: A 6 months prospective study 307
Autoimmune liver disease in a sicilian woman. 287
Effects of Chitosan on Plasma Lipids and Lipoproteins: A 4-Month Prospective Pilot Study 255
The Role of Nutraceuticals in Statin Intolerant Patients 252
REPORT OF A CASE OF MALIGNANT TUMOR-LIKE GASTRIC LESION BY CANDIDA IN A DIABETIC TREATED WITH CYCLOSPORINE FOR PSORIASIS AND REVIEW OF THE LITERATURE 247
Elevated blood Hsp60, its structural similarities and cross-reactivity with thyroid molecules, and its presence on the plasma membrane of oncocytes point to the chaperonin as an immunopathogenic factor in Hashimoto's thyroiditis 245
Daily use of extra virgin olive oil with high oleocanthal concentration reduced body weight, waist circumference, alanine transaminase, inflammatory cytokines and hepatic steatosis in subjects with the metabolic syndrome: A 2-month intervention study 240
Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study 239
Pasta Supplemented with Opuntia ficus-indica Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study 230
Clinical anatomic, immunomorphologic and molecular anatomic data suggest interplay of thyroidal molecules, autoantibodies and Hsp60 in Hashimoto’s disease 227
Lichen sclerosus as a cause of recurrent cystitis: case report and review of the literatury. 221
Liraglutide increases serum levels of microRNA27b,-130a and-210 in patients with type 2 diabetes mellitus: A novel epigenetic effect 220
Diagnostica non invasiva delle varici esofagee nei pazienti con cirrosi epatica: dati ecografici vs dati endoscopici 219
Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study 219
Osteodystrophy in chronic liver diseases. 218
Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients with Metabolic Syndrome 215
Management of Statin Intolerance in 2018: Still More Questions Than Answers 214
IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins 213
Cloni di carciofo "Romanesco" in coltura annuale in Sicilia 201
Liraglutide improves carotid intima-media thickness in patients with type-2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study 200
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. 196
Food hypersensitivity-associated irritable bowel syndrome: may fecal assays improve diagnosis? 194
The effect of bergamot on dyslipidemia 192
Gli effetti extraglicemici di liraglutide: Focus sui marker cardiometabolici 190
Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes 186
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study 186
MALIGNANT TUMOR-LIKE GAASTRIC LESION DUE TO CANDIDA ALBICANS IN A DIABETIC PATIENT TREATED WITH CYCLOSPORIN: A CASE REPORT AND REVIEW OF THE LITERATURE 185
O- Alkylation of a lignite humic acid by phase-transfer catalysis 179
Improving diagnostic accuracy in celiac disease diagnosis: antiendomysium antibody assay in the culture medium of duodenal biopsies. 176
A Nutraceutical Containing Chlorogenic Acid and Luteolin Improves Cardiometabolic Parameters in Subjects with Pre-Obesity: A 6-Month Randomized, Double-Blind, Placebo-Controlled Study 175
Improving diagnostic accuracy in Celiac Disease diagnosis: anti-endomysium antibody assay in colture medium of duodenal biopsies. 175
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect 172
Rare Candida albicans overgrowth in an immunosuppressed patient: case report of a malignant tumor-like gastric lesion. 171
The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives. 170
Malignant tumor-like gastric lesion by Candida albicans. 169
Food hypersensitivity in patients with irritable bowel syndrome: the diagnostic role of fecal assays. 168
Nutraceuticals as an important part of combination therapy in dyslipidaemia 168
Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation. 164
Effect of liraglutide on carotid intima-media thickness in patients with type-2 diabetes: a 4-month prospective study 163
Lichen sclerosus and atrophicus: report of a case of female patient affected with recurrent cystitis. 155
Effects of Liraglutide on Metabolic Parameters and Carotid Intima-Media Thickness in Patients with The Metabolic Syndrome: A 12-Month Prospective Pilot Study 153
Advances in pharmacological treatment of type 1 diabetes during pregnancy 152
Prevalence of antibodies anti-bartonella henselae in western Sicily: children, blood donors, cats 149
INCRETIN-BASED THERAPIES, GLUCOMETABOLIC HEALTH AND ENDOVASCULAR INFLAMMATION 148
Variazioni emodinamiche del circolo epatico in pazienti con bright liver ecopattern e sindrome metabolica 147
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes 147
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms 146
Effects of Liraglutide on Carotid Intima-Media Thickness in Patients with Type-2 Diabetes and Non-Alcoholic Fatty Liver Disease: An 8-Month Prospective Pilot Study 145
Anti-atherogenic Effects of 17β-Estradiol 145
A novel beneficial effect of liraglutide: the reduction in subclinical atherosclerosis in patients with type-2 diabetes. 143
Serological, immunomorphological and bioinformatics analyses suggest Hsp60 is involved in Hashimoto’s thyroiditis pathogenesis. 142
Smoking and small, dense low-density lipoproteins. 141
Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pilot study 134
Natural approaches in metabolic syndrome management 129
Polyphenols: Potential use in the prevention and treatment of cardiovascular diseases 128
Effects of liraglutide on plasma ghrelin concentrations and oxidative stress in patients with type 2 diabetes: a 2-month prospective pilot study. 120
PREVALENCE OF LIVER STEATOSIS AND FIBROSIS AND RELIABILITY OF ULTRASOUND IN DETECTING NAFLD IN OBESE PATIENTS 117
Nutraceuticals in Lipid-Lowering Treatment: A Narrative Review on the Role of Chitosan 114
Metabolic disorders during pregnancy and postpartum cardiometabolic risk 114
Novel therapeutical approaches to managing atherosclerotic risk 112
Prediction of vascular events in subjects with subclinical atherosclerosis and the metabolic syndrome: the role of markers of inflammation. 111
Future perspectives of the pharmacological management of diabetic dyslipidemia 111
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes 109
NUOVE STRATEGIE PER IL MANAGEMENT CLINICO, DIAGNOSTICO E TERAPEUTICO DELLE MALATTIE CARDIO-METABOLICHE 104
Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study 102
Pharmacotherapy for gestational diabetes 101
Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes 96
Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update 96
Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus 93
Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas? 86
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect 83
Diabetic cardiomyopathy: pathophysiology, imaging assessment and therapeutical strategies 82
Oxidative stress and small, dense low-density lipoproteins: Current and future perspectives 79
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies 77
Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes 72
Genetic and Epigenetic Biomarkers For Diagnosis, Prognosis and Treatment Of Metabolic Syndrome 66
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review. 64
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes 64
Obesity and HFpEF 62
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm? 53
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance 49
Impact of different hormones on the regulation of nitric oxide in diabetes 46
Totale 13.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.387
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.387
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022881 51 136 40 32 23 38 35 76 92 140 66 152
2022/20231.411 135 211 30 135 126 191 126 120 151 37 91 58
2023/2024681 35 91 53 43 44 143 85 37 20 18 34 78
2024/20251.558 29 172 113 143 67 55 116 80 116 168 183 316
2025/20265.016 344 158 252 456 548 694 666 518 442 573 129 236
2026/2027200 200 0 0 0 0 0 0 0 0 0 0 0
Totale 13.578